Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Flutiform Articles

SkyePharma partner Kyorin files for Flutiform approval in Japan

26 September 2012

SkyePharma/Mundipharma's Flutiform launched in Germany

23 September 2012

Flutiform receives UK regulatory approval; solid financials from SkyePharma

24 August 2012

European approval for Mundipharma/SkyePharma's asthma drug Flutiform

4 July 2012

SkyePharma partner Kyorin completes Japanese Flutiform clinical program

26 June 2012

Positive opinions from CHMP for Forxiga, Jakavi, Rienso and Flutiform but not Glybera

22 April 2012

Two hurdles to jump for SkyePharma, as it changes CEO

31 January 2012

Skyepharma updates on Exparel, Flutiform and financial position

14 November 2011

Flutiform review to take longer than expected, says SkyePharma

19 October 2011

SkyePharma in manufacturing alliance with Aenova Group; amends CRC finance facility

1 August 2011

Sanofi gets rights to SkyePharma’s Flutiform in Mexico, Central and South America

29 July 2011

SkyePharma regains US marketing rights to Flutiform from Abbott

23 August 2010

Skyepharma’s investment future hinges on Flutiform, say Edison analysts

12 April 2010

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS